# BRIUMVI

NDC: 73150-150
Generic name: ublituximab
Labeler / Manufacturer: TG Therapeutics, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION, CONCENTRATE
Routes: INTRAVENOUS
Marketing started: 20221228

FDA application: BLA761238

## Active ingredients

- UBLITUXIMAB: 150 mg/6mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73150-150"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73150-150
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a77cd8c-811b-407c-9140-d0c5c26435c2